Published in:
Open Access
01-05-2014 | Oral presentation
Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma
Authors:
Yibing Yan, Grant McArthur, Omid Hamid, Igor Puzanov, Rene Gonzalez, Thomas Gajewski, Yulei Wang, Matthew Wongchenko, Nicholas Choong, Antoni Ribas
Published in:
Journal of Translational Medicine
|
Special Issue 1/2014
Login to get access
Excerpt
Combined BRAF and MEK inhibition may delay the onset of resistance compared with BRAF inhibition alone. The safety and tolerability of the BRAF and MEK inhibitors, vemurafenib and cobimetinib were evaluated in a phase 1B trial, BRIM7 (NCT01271803). Modulation of signaling pathways, transcriptional outputs and T-cell dynamics were assessed in tumor samples obtained from BRIM7. …